Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...

LG Chem said Tuesday it has received US Food and Drug Administration clearance for its investigational new drug application to begin a phase 1/2 clinical trial ...

Lung cancer is the most common and deadly form of cancer worldwide. It is increasingly understood to be a complex genetic disease with different mutations that vary according to factors such as ...

HER2 mutations in advanced NSCLC: Prevalence, mutational context, and clinical outcomes from an Australian clinico-genomic database.

Adequate CD19-positive cell content is required to reliably identify both dominant and subclonal TP53 mutations. DNA was isolated in parallel from 2 different sample types from this patient: ...

Imagine a tiny superhero inside every cell of your body whose job is to stop damaged cells before they turn dangerous. That superhero is a gene called TP53, and for decades scientists have known it as ...

The prognostic impact of TP53 mutation on survival outcomes in ALK fusion–positive lung cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a ...